- Home
- SWIM vs ABUS Comparison
SWIM vs ABUS Comparison
Compare SWIM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- ABUS
- Stock Information
- Founded
- SWIM 1956
- ABUS 2005
- Country
- SWIM United States
- ABUS United States
- Employees
- SWIM N/A
- ABUS N/A
- Industry
- SWIM Plastic Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- ABUS Health Care
- Exchange
- SWIM Nasdaq
- ABUS Nasdaq
- Market Cap
- SWIM 916.0M
- ABUS 711.2M
- IPO Year
- SWIM 2021
- ABUS N/A
- Fundamental
- Price
- SWIM $7.75
- ABUS $4.43
- Analyst Decision
- SWIM Hold
- ABUS Strong Buy
- Analyst Count
- SWIM 3
- ABUS 2
- Target Price
- SWIM $6.93
- ABUS $5.00
- AVG Volume (30 Days)
- SWIM 590.2K
- ABUS 1.6M
- Earning Date
- SWIM 11-04-2025
- ABUS 11-05-2025
- Dividend Yield
- SWIM N/A
- ABUS N/A
- EPS Growth
- SWIM N/A
- ABUS N/A
- EPS
- SWIM N/A
- ABUS N/A
- Revenue
- SWIM $521,828,000.00
- ABUS $15,416,000.00
- Revenue This Year
- SWIM $9.17
- ABUS $138.02
- Revenue Next Year
- SWIM $5.38
- ABUS N/A
- P/E Ratio
- SWIM N/A
- ABUS N/A
- Revenue Growth
- SWIM N/A
- ABUS 53.23
- 52 Week Low
- SWIM $4.56
- ABUS $2.71
- 52 Week High
- SWIM $8.46
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- SWIM 50.03
- ABUS 63.83
- Support Level
- SWIM $7.67
- ABUS $4.37
- Resistance Level
- SWIM $8.06
- ABUS $5.10
- Average True Range (ATR)
- SWIM 0.28
- ABUS 0.26
- MACD
- SWIM -0.08
- ABUS 0.03
- Stochastic Oscillator
- SWIM 12.40
- ABUS 55.33
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.